NeXeption nabs $21.5 mln to form new company Alexar Therapeutics
NeXeption, a biopharmaceutical management company, said Thursday that it has closed $21.5 million in Series A financing. New Science Ventures and Third Point Ventures led the round with participation from Palo Alto Investors. According to NeXeption, the capital infusion will be used to launch Alexar Therapeutics, which will focus on developing Liver X receptor agonists. In conjunction with the funding, Dave Pfeiffer has been named CEO of Alexar while Steve Tullman, managing partner of NeXeption, will serve as chairman of Alexar's board of directors.
2 January 2014•4 mins read
